The COVAX facility, backed by the World Health Organization and the Global Alliance for Vaccines and Immunization, has delivered 1.55 billion COVID-19 vaccine doses to 146 countries. In December, COVAX set a target of achieving 70% COVID-19 immunization coverage by mid-2022.
Tag Archive for: AstraZeneca
Under the expanded deal, AstraZeneca’s will have access to Oxford Biomedica’s Oxbox manufacturing facility to produce its shot on an as-needed basis beyond 2022.
AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe, and a positive clinical trial update.
AstraZeneca said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery.
The company stated that two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company’s oncology portfolio.
An interim analysis of AstraZeneca and partner Ionis Pharmaceuticals’ eplontersen showed the experimental drug met the main goals in a late-stage trial in patients with a rare, fatal disease, the Anglo-Swedish drugmaker said on Tuesday.
Pharmaceutical powerhouse AstraZeneca appears to have taken an interest in the company’s London-based partner Mereo BioPharma and may be considering a buyout, according to circulating speculations first reported by The Times UK.
The values of leading pharmaceutical brands have skyrocketed during the COVID-19 pandemic; Johnson & Johnson retains the top position.
Although a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe — Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca-Oxford — a number of companies are continuing to develop vaccines in hopes they can be used as booster shots.
GSK aims to get the company’s respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly watched late-stage study involving older adults.